206.26

2.01% -4.23

After Hours: 204.50 -1.76 -0.85%

Iqvia Holdings Inc (IQV)

Overview News Price History Option Chain Financials Discussions Forecast

Iqvia Holdings Inc stock is traded at $206.26, with a volume of 1.26M. It is down -2.01% in the last 24 hours and up +20.85% over the past month. Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Previous Close:

$210.49

Open:

$207.15

24h Volume:

1.26M

Relative Volume:

0.78

Market Cap:

$34.42B

Revenue:

$16.63B

Net Income/Loss:

$1.39B

P/E Ratio:

25.57

EPS:

8.0674

Net Cash Flow:

$2.12B

1W Performance:

-0.76%

1M Performance:

+20.85%

6M Performance:

-13.22%

1Y Performance:

+26.35%

1-Day Range:

$205.80

$211.64

1-Week Range:

$202.76

$212.36

52-Week Range:

$154.50

$247.04

Iqvia Holdings Inc Stock (IQV) Company Profile

Name

Iqvia Holdings Inc

Sector

Healthcare (1092)

Industry

Diagnostics & Research (49)

Phone

919-998-2000

Address

2400 ELLIS ROAD, DURHAM, NC

Employee

93,000

Twitter

@IQVIA_global

Next Earnings Date

2026-07-28

Latest SEC Filings

IQV's Discussions on Twitter

Compare IQV vs TMO, DHR, IDXX, NTRA, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IQV Iqvia Holdings Inc	206.26	35.13B	16.63B	1.39B	2.12B	8.0674
TMO Thermo Fisher Scientific Inc	532.48	201.86B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	203.83	145.10B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	567.44	45.44B	4.45B	1.10B	1.06B	13.59
NTRA Natera Inc	271.39	38.64B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	131.46	38.44B	7.23B	1.41B	1.09B	4.979

Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Upgrade	TD Cowen	Hold → Buy
Mar-06-26	Upgrade	Barclays	Equal Weight → Overweight
Mar-03-26	Initiated	RBC Capital Mkts	Outperform
Dec-02-25	Resumed	Morgan Stanley	Overweight
Nov-13-25	Initiated	BMO Capital Markets	Outperform
Nov-03-25	Downgrade	TD Cowen	Buy → Hold
Oct-29-25	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-09-25	Upgrade	HSBC Securities	Hold → Buy
Sep-09-25	Upgrade	Jefferies	Hold → Buy
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform
Jul-24-24	Downgrade	Jefferies	Buy → Hold
Jun-06-24	Initiated	Goldman	Buy
Feb-26-24	Initiated	Leerink Partners	Outperform
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral
Sep-06-23	Initiated	HSBC Securities	Buy
Mar-17-23	Initiated	Truist	Buy
Dec-06-22	Initiated	Cowen	Outperform
Nov-17-22	Downgrade	Citigroup	Buy → Neutral
Aug-25-22	Initiated	Credit Suisse	Outperform
Jul-15-22	Initiated	SVB Leerink	Outperform
May-24-22	Initiated	Guggenheim	Buy
Apr-29-22	Upgrade	Piper Sandler	Neutral → Overweight
Apr-25-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-05-21	Resumed	Credit Suisse	Outperform
Apr-16-21	Upgrade	Stephens	Equal-Weight → Overweight
Mar-08-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-03-21	Initiated	Barclays	Overweight
Jul-07-20	Initiated	Stephens	Equal-Weight
Mar-02-20	Initiated	Deutsche Bank	Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Upgrade	CFRA	Sell → Hold
Nov-14-19	Upgrade	Wolfe Research	Peer Perform → Outperform
Jun-21-19	Upgrade	Mizuho	Neutral → Buy
May-28-19	Initiated	SVB Leerink	Outperform
Jan-18-19	Upgrade	Jefferies	Hold → Buy
Oct-09-18	Initiated	UBS	Buy
Oct-02-18	Reiterated	Robert W. Baird	Outperform
Jul-25-18	Upgrade	BofA/Merrill	Neutral → Buy
Jul-25-18	Reiterated	Stifel	Buy
Jul-03-18	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-18	Upgrade	Goldman	Neutral → Buy
Mar-07-18	Upgrade	SunTrust	Hold → Buy
Jan-19-18	Initiated	Evercore ISI	Outperform

View All

Iqvia Holdings Inc Stock (IQV) Latest News

Jul 17, 2026

IQVIA Holdings stock trades steadily as data-driven growth supports valuations - ad-hoc-news.de

Jul 17, 2026

IQVIA Holdings (NYSE: IQV) awards director 160 deferred share units - Stock Titan

Jul 16, 2026

IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Jul 16, 2026

IQVIA Seeks Faster Path From Discovery to Human Drug Trials - Stock Titan

Jul 16, 2026

IQVIA Holdings' Q2 2026 earnings: What to expect - MSN

Jul 16, 2026

IQVIA executive testifies on U.S. clinical trial improvements By Investing.com - Investing.com South Africa

Jul 16, 2026

Jul 15, 2026

IQVIA Holdings (IQV) Q1 2026 Earnings Call Transcript - Fortune

Jul 15, 2026

Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.

Jul 15, 2026

Jul 14, 2026

IQVIA Holdings stock reflects data-driven growth in global healthcare analytics - ad-hoc-news.de

Jul 14, 2026

IQV vs. PEN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada

Jul 14, 2026

Jul 13, 2026

IQVIA stock holds steady as its data and research model stays central - ad-hoc-news.de

Jul 13, 2026